Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 6 August 2009, Vol. 114, No. 6, pp. 1150-1157.
Prepublished online as a Blood First Edition Paper on April 28, 2009; DOI 10.1182/blood-2009-01-202606.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2009-01-202606v1
114/6/1150    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Lane, S. W.
Right arrow Articles by Gilliland, D. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lane, S. W.
Right arrow Articles by Gilliland, D. G.
Related Collections
Right arrow Free Research Articles
Right arrow Myeloid Neoplasia
Right arrow Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

REVIEW ARTICLE

The leukemic stem cell niche: current concepts and therapeutic opportunities

Steven W. Lane1,2, David T. Scadden35, and D. Gary Gilliland1,46

1 Division of Hematology, Brigham and Women's Hospital, Boston, MA; 2 University of Queensland, Brisbane, Australia; 3 Massachusetts General Hospital, Boston; 4 Harvard Stem Cell Institute, Boston, MA; 5 Harvard University Department of Stem Cell and Regenerative Biology, Boston, MA; and 6 Howard Hughes Medical Institute, Boston, MA

The genetic events that contribute to the pathogenesis of acute myeloid leukemia are among the best characterized of all human malignancies. However, with notable exceptions such as acute promyelocytic leukemia, significant improvements in outcome based on these insights have not been forthcoming. Acute myeloid leukemia is a paradigm of cancer stem (or leukemia initiating) cells with hierarchy analogous to that seen in hematopoiesis. Normal hematopoiesis requires complex bidirectional interactions between the bone marrow microenvironment (or niche) and hematopoietic stem cells (HSCs). These interactions are critical for the maintenance of normal HSC quiescence and perturbations can influence HSC self-renewal. Leukemia stem cells (LSCs), which also possess limitless self-renewal, may hijack these homeostatic mechanisms, take refuge within the sanctuary of the niche during chemotherapy, and consequently contribute to eventual disease relapse. We will discuss the emerging evidence supporting the importance of the bone marrow microenvironment in LSC survival and consider the physiologic interactions of HSCs and the niche that inform our understanding of microenvironment support of LSCs. Finally, we will discuss approaches for the rational development of therapies that target the microenvironment.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
A. Tefferi and J. W. Vardiman
Myelodysplastic Syndromes
N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885.
[Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020